Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Biochips in Drug Development

26.06.2003


Figure 1: Ligand fishing (BIA-MS coupling)


Figure 2: ADME assays of small compounds binding to HSA


Biomolecular interaction analysis (BIA) using SPR (surface plasmon resonance) biosensors is now utilised increasingly in nearly all phases of drug development. The BIA system consists out of a light source emitting near infrared light, a sensor microchip, an automated liquid handling system with constant flow and a diode array position-sensitive detector. One of the two interacting partners (referred to as the ligand) is immobilized on the sensor surface. The other binding partner, called the analyte, is directed over the surface in a constant flow system allowing to monitor the interaction of the binding partners in “real time”.

BIA covers a broad range of applications in target identification and validation, secondary screens and lead optimisation, early ADME assays as well as testing immunoreactivity.

Assay development and functional assays of proteins are the most commonly used areas of applications of BIA in drug development.



Advantages of SPR-based measurements are the possibility to measure in real time without the need of labelling yielding highly reproducible kinetic data with low sample consumption.

Ligand fishing

BIA-technology is ideally suited as a micro-affinity purification platform allowing on-line detection of binding events and the direct quantification of bound material on biological surfaces of interest.

Kinetic parameters may be obtained as additional information. Provided that a binding partner has been captured on the sensor chip it can be recovered by a gentle elution for further downstream analyses like mass spectrometry or western blot analysis (see figure 1).

In comparison to classical chromatographic methods biosensor systems show reduced unspecific binding, are compatible with small volume recovery and are readily automated.

The identification of unknown ligands is of particular interest for revealing function of orphan receptors, for the detection of cellular interaction networks and for testing the biocompatibility of novel surface coatings.

Target validation

Genomics and proteomics based techniques have provided a lot of new potential targets which has to be validated to prove that a DNA, RNA or protein molecule is directly involved in a disease process and is therefore a suitable target for the development of new therapeutic compounds.

The assessment of biological function, involvement in biological pathways and role in pathogenesis of potential targets can be achieved by mapping and validation of protein interaction networks in vivo and in vitro.

Yeast two hybrid and phage display are classical approaches for systematic protein interaction screening capable to probe millions of interactions. Positives obtained from these screening technologies can be validated using BIA technology.

Furthermore, additional parameters relevant for the interaction of interest can be investigated. This could be interactions with multiple components, effects of cofactors, pH-changes or the role of posttranslational modifications.

Lead optimisation

Hit validation is needed to determine whether a molecule identified in a screen or assay will eventually lead to a drug.

Therefore secondary assays generating data about potency, selectivity and functional biochemical activity have to be performed.

BIA technology has an enormous capability for the rapid confirmation of hits from high throughput screens by a comprehensive kinetic characterisation of potential lead compounds.

Information about affinities, rates of association and dissociation in complex formation and binding stoichiometries is very valuable for a ranking and optimisation of lead compounds. Even compounds binding with low affinity or transient kinetics, often found in early phases of drug development, can accurately be identified.

The kinetic information obtained by functional assays together with the knowledge about structural properties of biomolecules allows predictions on structure activity relationships.

Lead optimisation is an iterative process involving computer-assisted molecular modelling, chemical synthesis of new compounds and functional assays.

BIA technology is used in lead optimisation by linking compound structural information with a comprehensive kinetic characterisation of ligand binding.

ADME

ADME assays (adsorption, distribution, metabolism, elimination) become more and more important even in the earlier phases of the drug development process.

BIA assays provide very valuable information for a cost-effective in vitro characterisation of potential drug candidates in early ADME studies, although there are no methods available for accurately predicting what will happen to a drug in vivo.

SPR biosensor technology has already been applied for the binding of potential drug candidates to serum proteins, for analysing the adsorption of small molecules to artificial membranes immobilised on sensor chips and for measuring the influence of compounds on metabolic pathways.

The pharmacokinetic properties of small molecule drugs are a function of the reversible binding to serum proteins such as serum albumin, alpha 1-acid glycoprotein or gamma globulins, reducing the bioavailibility of the drug (see figure 2).

Biaffin offers a BIA assay for analysing the binding of small molecule compounds to high density serum protein surfaces yielding valuable information about affinitiy, solubility and binding stoichiometry of potential drug candidates.

Immune response

Newly designed pharmaceuticals can cause an unwanted immune response. In preclinical studies such potentials can be recognised in animal studies.

BIA technology can detect antibodies against new drugs in animal serum samples. With appropriate control experiments positive binding signals of low antibody levels can clearly be identified as a specific signal despite of the complexity of the protein mixture in serum samples.

Dr. Stephan Drewianka | Biaffin GmbH & Co KG
Further information:
http://www.biaffin.com/drug_development.htm
http://www.innovations-report.de/html/profile/profil-1117.html

More articles from Health and Medicine:

nachricht New nanomedicine slips through the cracks
24.04.2019 | University of Tokyo

nachricht Sugar entering the brain during septic shock causes memory loss
23.04.2019 | Rensselaer Polytechnic Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Energy-saving new LED phosphor

The human eye is particularly sensitive to green, but less sensitive to blue and red. Chemists led by Hubert Huppertz at the University of Innsbruck have now developed a new red phosphor whose light is well perceived by the eye. This increases the light yield of white LEDs by around one sixth, which can significantly improve the energy efficiency of lighting systems.

Light emitting diodes or LEDs are only able to produce light of a certain colour. However, white light can be created using different colour mixing processes.

Im Focus: Quantum gas turns supersolid

Researchers led by Francesca Ferlaino from the University of Innsbruck and the Austrian Academy of Sciences report in Physical Review X on the observation of supersolid behavior in dipolar quantum gases of erbium and dysprosium. In the dysprosium gas these properties are unprecedentedly long-lived. This sets the stage for future investigations into the nature of this exotic phase of matter.

Supersolidity is a paradoxical state where the matter is both crystallized and superfluid. Predicted 50 years ago, such a counter-intuitive phase, featuring...

Im Focus: Explosion on Jupiter-sized star 10 times more powerful than ever seen on our sun

A stellar flare 10 times more powerful than anything seen on our sun has burst from an ultracool star almost the same size as Jupiter

  • Coolest and smallest star to produce a superflare found
  • Star is a tenth of the radius of our Sun
  • Researchers led by University of Warwick could only see...

Im Focus: Quantum simulation more stable than expected

A localization phenomenon boosts the accuracy of solving quantum many-body problems with quantum computers which are otherwise challenging for conventional computers. This brings such digital quantum simulation within reach on quantum devices available today.

Quantum computers promise to solve certain computational problems exponentially faster than any classical machine. “A particularly promising application is the...

Im Focus: Largest, fastest array of microscopic 'traffic cops' for optical communications

The technology could revolutionize how information travels through data centers and artificial intelligence networks

Engineers at the University of California, Berkeley have built a new photonic switch that can control the direction of light passing through optical fibers...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

Fraunhofer FHR at the IEEE Radar Conference 2019 in Boston, USA

09.04.2019 | Event News

 
Latest News

Proteins stand up to nerve cell regression

24.04.2019 | Life Sciences

New sensor detects rare metals used in smartphones

24.04.2019 | Life Sciences

Controlling instabilities gives closer look at chemistry from hypersonic vehicles

24.04.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>